Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vevye for Meibomian Gland Dysfunction
NCT07224529Phase 4Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cyclosporine ophthalmic solution in meibomian gland dysfunction (MGD), sponsored by University of Alabama at Birmingham. Started Jun 2026; status: recruiting.
02
Drugs
cyclosporine ophthalmic solution
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT07224529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224529.